Leidos Awarded Contract by National Institutes of Health

Company to Provide Information Technology Services in Support of the Electronic Research Administration

News provided by

Dec 01, 2014, 08:05 ET

RESTON, Va., Dec. 1, 2014 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health and engineering solutions company, was awarded a prime contract by the National Institutes of Health (NIH) to provide information technology services in support of the Electronic Research Administration (eRA). The single-award cost-plus fixed-fee contract has a one-year base period of performance, four one-year options and a total contract value of approximately $113 million if all options are exercised. Work will be performed in Bethesda, Md.

The eRA provides electronic systems support to manage the receipt, processing, review, award, and monitoring of billions of dollars' worth of research and non-research grants awarded annually. These grants are funded by NIH in support of the mission of improving human health.

Under the contract, Leidos will provide IT services necessary to support eRA in the development, maintenance, and implementation of systems that are designed to accommodate NIH and Department of Health and Human Services initiatives. Leidos will also provide design and development services to the government for all eRA program modules throughout the software development lifecycle. The end products shall be modules of production quality, which will enhance and integrate with the existing eRA modules and provide substantial new functionality.

"This important program enables the synthesis of data into knowledge that can guide the management of the NIH research portfolio to help improve the nation's health," said Steve Comber, Group President of Leidos Health. "We're pleased to continue to help the NIH enhance the functionality and usability of the grants management system and further its medical research goals."

About Leidos Health

As a leader for more than 25 years in the healthcare industry, Leidos Health fuses some of the world's most advanced technologies with the brightest minds in science, research and consulting. Today, Leidos Health is focused on developing next-generation solutions in areas such as biomedical research, public health and health analytics to turn data into actionable information for clinicians and their patients. From leading groundbreaking medical research to fighting diseases such as cancer, AIDS and malaria, to implementing and optimizing electronic health records that enhance the research process and improve critical efficiencies – Leidos Health's passion to improve patient care and reduce costs is helping to transform healthcare. For more information, visit www.Leidos.com/health.

About Leidos

Leidos is a FORTUNE 500^® science and technology solutions leader working to address some of the world's toughest challenges in national security, health and engineering. The Company's 21,000 employees support vital missions for our government and the commercial sector, develop innovative solutions to drive better outcomes and defend our Nation's digital and physical infrastructure from 'new world' threats. Headquartered in Reston, Va., Leidos reported annual revenues of approximately $5.77 billion for its fiscal year ended January 31, 2014 after giving effect to the spin-off of the company's technical services and information technology business. For more information, visit www.Leidos.com.

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 31, 2014, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.